Type 2 Diabetes
Type 2 diabetes (T2D) is a chronic metabolic condition characterised by progressive hyperglycaemia driven by insulin resistance and declining pancreatic beta-cell function. Unlike Type 1 diabetes, it is not autoimmune in origin and typically develops in adults, though earlier onset is increasingly common with rising global obesity rates. It affects approximately 537 million adults worldwide (2021 IDF estimate) and is associated with elevated risks of cardiovascular disease, chronic kidney disease (CKD), neuropathy, retinopathy, and limb amputation.
The standard treatment pathway follows a stepwise approach endorsed by the ADA and EASD. Lifestyle modification and metformin are first-line interventions. When blood sugar targets are not met, second-line agents are added based on comorbidities: SGLT2 inhibitors or GLP-1 receptor agonists are preferred when cardiovascular disease, heart failure, or CKD is present. When oral agents fail, injectable therapy is introduced — typically a GLP-1 receptor agonist or basal insulin. As beta-cell function continues to decline, prandial (bolus) insulin may be required on top of basal insulin, representing the most complex, burdensome treatment regimen.
Glycaemic control is typically measured by HbA1c (glycated haemoglobin), a 3-month average of blood glucose. Most guidelines target HbA1c below 7.0% (53 mmol/mol), though targets are individualised based on age, hypoglycaemia risk, comorbidities, and patient preference. Advanced T2D — typically defined as disease requiring insulin treatment, long diabetes duration (>10 years), or the presence of complications — presents particular therapeutic challenges: patients are at higher risk of hypoglycaemia on insulin, have greater cardiovascular and renal comorbidity, and often have declining beta-cell reserve.
The distinction between early and advanced T2D is critical when evaluating tirzepatide evidence. Most SURPASS-programme participants had relatively short diabetes duration (mean 4.7–13 years) and baseline HbA1c 7.9–8.8%, and were overweight or obese (mean BMI 31.9–35.8 kg/m²). This means SURPASS data may not fully represent patients with very advanced disease, severe insulin deficiency, or frailty. Patients aged 50+ with long diabetes duration, sarcopenia risk, or established nephropathy are underrepresented in the primary trial populations.
Ontology Type 2 Diabetes [relates] HbA1c Reduction Type 2 Diabetes [relates] Insulin-Use Reduction Type 2 Diabetes [relates] Kidney Outcomes Type 2 Diabetes [relates] Tirzepatide Type 2 Diabetes [relates] Semaglutide Type 2 Diabetes [relates] Insulin Glargine Type 2 Diabetes [relates] SURPASS Clinical Trial Programme Type 2 Diabetes [defines] Beta-Cell Function Type 2 Diabetes [relates] Cardiovascular Risk Type 2 Diabetes [relates] Sarcopenia Risk in Older Adults
Treatment Context
- Standard treatment pathway: Lifestyle → metformin → add SGLT2i/GLP-1 RA (if CVD/CKD) or DPP-4i/SU → basal insulin → basal-bolus insulin
- Where tirzepatide fits: ADA 2023 guidelines position dual GIP/GLP-1 receptor agonists as a second-line option with strong glucose-lowering and weight-loss benefit; preferred over basal insulin for patients prioritising weight loss or hypoglycaemia avoidance; not yet positioned above SGLT2 inhibitors for CVD/CKD unless glucose control is primary concern
- Where insulin fits: Required in advanced disease with beta-cell failure; basal insulin adds glycaemic stability when fasting glucose elevated; prandial insulin addresses postprandial excursions
- Advanced disease considerations: SURPASS-4 and SURPASS-6 show tirzepatide can replace or delay prandial insulin intensification in patients on basal insulin; data in patients already on basal-bolus regimens are limited
Connections
- Tirzepatide — treats_or_manages, [2022–present], source: FDA approval 2022
- HbA1c Reduction — measured_by, [2019–2023], source: SURPASS programme
- Insulin-Use Reduction — measured_by, [2021–2023], source: SURPASS-3, SURPASS-6
- Kidney Outcomes — measured_by (post-hoc), [2022], source: PMID 36152639
- SURPASS Clinical Trial Programme — evidence_source, [2019–2023]
- Sarcopenia Risk in Older Adults — evidence_gap_for, [2024], source: EvidenceGaps/